CD8A and B-cell chronic lymphocytic leukemia: The multi-peptide vaccine CLL-VAC-XS15 comprises naturally presented non-mutated CLL-associated antigens expected to induce multiple leukemia-specific CD8+ and CD4+ T-cell responses that lead to the killing of residual CLL cells and thus protection from disease relapse, eventually resulting in prolonged survival.